Literature DB >> 22160039

Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Adele K Fielding1.   

Abstract

The author discusses both the standards of care and more controversial areas in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22160039     DOI： 10.1182/asheducation-2011.1.231

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  14 in total

1.  Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.

Authors:  S Nishiwaki; K Imai; S Mizuta; H Kanamori; K Ohashi; T Fukuda; Y Onishi; S Takahashi; N Uchida; T Eto; H Nakamae; T Yujiri; S Mori; T Nagamura-Inoue; R Suzuki; Y Atsuta; J Tanaka
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

2.  Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.

Authors:  J-C Kim; S-H Shin; H G Yi; S-H Kim; S-I Woo; D-H Kim; K-S Park; J Kwan
Journal:  Herz       Date:  2013-02-23       Impact factor: 1.443

3.  Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

Authors:  Farhad Ravandi; Jeffrey L Jorgensen; Deborah A Thomas; Susan O'Brien; Rebecca Garris; Stefan Faderl; Xuelin Huang; Sijin Wen; Jan A Burger; Alessandra Ferrajoli; Partow Kebriaei; Richard E Champlin; Zeev Estrov; Pramoda Challagundla; Sa A Wang; Rajyalakshmi Luthra; Jorge E Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

4.  Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant.

Authors:  Adele K Fielding
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 5.  Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Matt Stevenson; Abdullah Pandor; Jean Hamilton; John Stevens; Clare Rowntree; Marrissa Martyn-St James; Andrew Rawdin; Ruth Wong
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

6.  Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study.

Authors:  E Hulegårdh; H Hägglund; L Ahlberg; K Karlsson; H Karbach; A Markuszewska; I Persson; M Åström; H Hallböök
Journal:  Med Oncol       Date:  2014-06-26       Impact factor: 3.064

7.  Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Farhad Ravandi; Susan M O'Brien; Jorge E Cortes; Deborah M Thomas; Rebecca Garris; Stefan Faderl; Jan A Burger; Michael E Rytting; Alessandra Ferrajoli; William G Wierda; Srdan Verstovsek; Richard Champlin; Partow Kebriaei; Deborah A McCue; Xuelin Huang; Elias Jabbour; Guillermo Garcia-Manero; Zeev Estrov; Hagop M Kantarjian
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

8.  Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.

Authors:  Fangfang Shi; Yamei Len; Yuping Gong; Rui Shi; Xi Yang; Duolan Naren; Tianyou Yan
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

9.  Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia.

Authors:  X-Q Weng; Y Shen; Y Sheng; B Chen; J-H Wang; J-M Li; J-Q Mi; Q-S Chen; Y-M Zhu; C-L Jiang; H Yan; X-X Zhang; T Huang; Z Zhu; Z Chen; S-J Chen
Journal:  Blood Cancer J       Date:  2013-08-16       Impact factor: 11.037

Review 10.  From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies.

Authors:  Maria Ciccone; George A Calin; Danilo Perrotti
Journal:  Front Oncol       Date:  2015-02-16       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.